Autonomix Medical, Inc. Common Stock AMIX

Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.

AMIX hizo una agrupación de acciones (split inverso) de 1:21 el 24 de junio de 2026: cada 21 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 24 ago

  Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

  Autonomix Medical announced a warrant inducement agreement with an investor to exercise outstanding July 2026 Warrants for 857,462 shares at $5.75 per share, generating approximately $4.9 million in gross proceeds. In exchange, the company issued new Series E-1 and E-2 warrants to purchase 535,913 shares each at $6.25 per share. The transaction is expected to close on August 26, 2026.

  

• GlobeNewswire Inc. 24 jul

  Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

  Autonomix Medical announced positive preclinical study results showing its neural sensing platform can detect, localize, and confirm changes in renal neural activity. The technology enables physiological feedback during renal denervation procedures, potentially addressing current limitations where physicians rely on anatomical landmarks rather than direct neural information. The company plans further preclinical and clinical studies to evaluate physiology-guided renal denervation applications.

  

• GlobeNewswire Inc. 13 jul

  Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

  Autonomix Medical announced a warrant inducement agreement where an investor will exercise outstanding warrants to purchase 428,731 shares at $6.00 per share, generating approximately $2.6 million in gross proceeds. In return, the company will issue new Series D-1 and D-2 warrants with a $5.75 exercise price. The transaction is expected to close on or about July 15, 2026.